2016 Revision of WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, Non-Hematopathologist, (Part 2 of 2)

November 17, 2016 9:00am CST

Review the most important changes to the WHO hematopathology classification system as part of the 2016 revision. Emphasis will be placed on presenting the information so that it is relevant and understandable by non-hematopathologists and laboratory staff. This will be a two-part presentation, with the first lecture covering lymphoid neoplasms and the second presentation covering myeloid and precursor neoplasms. September 15, 2016 was part one of the series.

  • Understand the need for the 2016 revision to the 2008 WHO hematopathology classification system.
  • Review pertinent changes involving lymphoid neoplasms in a manner understandable by general pathologists and laboratory staff.
  • Illustrate important situations where advanced testing (e.g. IHC, molecular, FISH) may be helpful in further distinguishing hematopoietic neoplasms, which had been difficult to classify or confirm with certainty in the past.

Philip Ferguson, MD is a practicing pathologist in private practice located in Arkansas. He has a diverse training background that includes an undergraduate degree in mechanical engineering, post-graduate training in internal medicine, and board certifications in anatomic pathology, clinical pathology, and hematopathology. His professional interests center on educational resource development for pathologists and trainees, and use of immunohistochemistry and molecular diagnostics in surgical pathology. Dr. Ferguson launched one of the first widespread internet educational tools for pathology residents to prepare for their board examination, PathMD (www.PathMD.com), which is now the Leica tool PathLead. Dr. Ferguson also serves as a state commissioner for the College of American Pathologists' Accreditation and Laboratory Improvement Program and is also member of the Global Advisory Board for Leica Biosystems. Dr. Ferguson has published several publication of late including ‘Effects of a Multidisciplinary Approach to Improve Volume of Diagnostic Material in CT-Guided Lung Biopsies’ in 2015.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec consequat dignissim felis sollicitudin congue. Sed odio diam, dapibus in maximus in, ultrices lacinia nibh. Nulla ipsum nisl, sollicitudin id magna nec, ultricies pulvinar dui. Maecenas sit amet metus tortor. Nullam dictum enim sed pulvinar mollis. Cras pretium, ex at volutpat aliquam, eros neque cursus diam, quis venenatis quam libero a mi. Etiam vel justo eu est feugiat pharetra. Phasellus elementum sollicitudin condimentum. Integer at nulla quam. Duis odio dui, sodales sed mattis eget, consectetur in tortor. Sed laoreet elit mattis massa dignissim porta. Phasellus felis orci, aliquam ac nulla elementum, convallis efficitur magna. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce iaculis tellus feugiat turpis porttitor tristique. Quisque ac faucibus metus. Integer nec dolor elit.

 

ABOUT US


Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

Register for your Complimentary Webinar

I agree that Leica Biosystems may collect and further process my personal data in accordance with its Privacy Policy.